8-K: American Healthcare REIT Announces Executive Bonuses, First Quarter Distribution, and Responds to Amended Tender Offer

American Healthcare REIT disclosed 2023 executive bonuses, a first quarter 2024 distribution of $0.25 per share, and responded to an amended unsolicited tender offer from Comrit Investments.

Summary

• American Healthcare REIT's board approved 2023 short-term incentive program compensation for named executive officers, which were not included in the previous prospectus.
• The cash bonuses for the CEO, Danny Prosky, totaled $949,500, while other executives received bonuses ranging from $296,244 to $601,350.
• The company also disclosed severance compensation amounts for each executive under various termination scenarios.
• The CEO's total compensation for 2023 was $3,784,680, and the median employee's total compensation was $122,976, resulting in a CEO-to-median employee pay ratio of 30.8 to 1.
• The board of directors has declared a first quarter 2024 distribution of $0.25 per share, payable on April 19, 2024, to shareholders of record as of March 28, 2024.
• The company responded to an amended mini-tender offer from Comrit Investments, which reduced its offer price to $5.23 per share from an initial $13.15 per share.
• The board has remained neutral on the Comrit offer, advising shareholders to make their own decisions after consulting with financial advisors.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The distribution is positive, but the significantly reduced tender offer price and the board's neutral stance create uncertainty and concern.

Positives

• The company has declared a first quarter 2024 distribution of $0.25 per share, providing a return to shareholders.
• The company is transparently disclosing executive compensation details, including bonuses and severance packages.
• The company is providing information to shareholders regarding the unsolicited tender offer, allowing them to make informed decisions.

Negatives

• Comrit Investments significantly reduced its tender offer price from $13.15 to $5.23 per share, which is substantially below the closing price of $13.80 per share of AHR common stock on the NYSE as of March 14, 2024.
• The board has remained neutral on the Comrit offer, which may leave some shareholders uncertain about the best course of action.
• The company acknowledges that the Class T and Class I common stock have limited liquidity until their automatic conversion on August 5, 2024.

Risks

• The Comrit tender offer is considered an opportunistic attempt to purchase shares at a low price.
• There is no guarantee that a public trading market for the listed common stock will develop or be liquid after the automatic conversion on August 5, 2024.
• The trading price of AHR common stock at the time of automatic conversion may not equal or exceed the Comrit Offer Price.
• Shareholders who tender their shares will lose their right to receive any future distributions with a record date after the sale of their shares to Comrit.

Future Outlook

The company's Class T and Class I common stock will automatically convert into listed common stock on August 5, 2024, but there is no guarantee of a liquid trading market or a specific trading price at that time.

Management Comments

• The Board MAKES NO RECOMMENDATION with respect to the Comrit tender offer, as amended March 15, 2024.
• The Board believes that the Comrit Offer, as amended, represents an opportunistic attempt by Comrit to purchase the Shares and make a profit.
• It is the general position of the Board to not make a recommendation with respect to tender offers and for each stockholder to evaluate such offers factoring their unique circumstances.
• None of AHRs directors or executive officers intends to tender any shares in the Comrit Offer, as amended.

Industry Context

The response to the unsolicited tender offer highlights the challenges and risks associated with mini-tender offers, which are often used to exploit investors. The company's focus on healthcare real estate is consistent with the broader trend of investment in stable, income-producing assets.

Comparison to Industry Standards

• The CEO pay ratio of 30.8 to 1 is within the range of other publicly traded REITs, but the specific ratio varies widely based on company size, complexity, and compensation philosophy.
• The distribution rate of $1.00 per share annualized is competitive with other healthcare REITs, but the actual yield will depend on the stock price.
• The Comrit tender offer at $5.23 per share is significantly below the market price of $13.80 per share, which is unusual for a tender offer and indicates a potential attempt to acquire shares at a discount.
• Companies such as Welltower (WELL) and Ventas (VTR) are comparable in the healthcare REIT space, but their specific financial metrics and tender offer situations would need to be compared directly to AHR.

Stakeholder Impact

• Shareholders are impacted by the distribution, the tender offer, and the future conversion of stock.
• Employees are impacted by the disclosure of the CEO pay ratio.
• The company's reputation is impacted by the response to the unsolicited tender offer.

Next Steps

• Shareholders need to decide whether to tender their shares in the Comrit offer by March 31, 2024.
• The company will pay the first quarter distribution on April 19, 2024.
• Class T and Class I common stock will automatically convert into listed common stock on August 5, 2024.

Key Dates

Keywords

executive compensation, cash bonuses, tender offer, distribution, shareholders, Comrit Investments, pay ratio, severance, NYSE, stock conversion